Headlines about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive this week, according to Alpha One. Alpha One, a subsidiary of Accern, rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of 0.10 on Alpha One’s scale. Alpha One also gave headlines about the biopharmaceutical company an impact score of 85 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Alpha One Sentiment’s rankings:
Shares of Bristol-Myers Squibb (BMY) opened at 52.36 on Tuesday. Bristol-Myers Squibb has a 1-year low of $46.01 and a 1-year high of $77.12. The company has a market cap of $86.26 billion, a price-to-earnings ratio of 18.19 and a beta of 1.00. The firm has a 50-day moving average price of $54.40 and a 200 day moving average price of $55.18. Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.12. Bristol-Myers Squibb had a return on equity of 31.39% and a net margin of 22.94%. The firm had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. During the same quarter in the previous year, the business earned $0.74 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb will post $2.95 EPS for the current fiscal year.
In related news, SVP Joseph C. Caldarella sold 8,096 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $57.29, for a total value of $463,819.84. Following the sale, the senior vice president now owns 55,637 shares of the company’s stock, valued at approximately $3,187,443.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lamberto Andreotti sold 34,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $53.26, for a total transaction of $1,810,840.00. Following the completion of the sale, the director now directly owns 952,571 shares in the company, valued at approximately $50,733,931.46. The disclosure for this sale can be found here. Insiders sold a total of 98,096 shares of company stock worth $5,421,270 in the last 90 days. Company insiders own 0.24% of the company’s stock. Bristol-Myers Squibb Company Profile